Bibliographic Details
| Title: |
Identification of Natural Products as SENP2 Inhibitors for Targeted Therapy in Heart Failure |
| Authors: |
Somayye Taghvaei, Farzaneh Sabouni, Zarrin Minuchehr |
| Source: |
Frontiers in Pharmacology, Vol 13 (2022) |
| Publisher Information: |
Frontiers Media S.A., 2022. |
| Publication Year: |
2022 |
| Collection: |
LCC:Therapeutics. Pharmacology |
| Subject Terms: |
SENP2, natural compounds, betanin, heart failure, molecular docking, molecular dynamics simulation, Therapeutics. Pharmacology, RM1-950 |
| More Details: |
Aims: Sentrin-specific protease -2 (SENP2) is involved in deSUMOylation. Increased deSUMOylation in murine hearts by SENP2 upregulation resulted in cardiac dysfunction and congenital heart defects. Natural compounds via regulating cell proliferation and survival, induce cell cycle cessation, cell death, apoptosis, and producing reactive oxygen species and various enzyme systems cause disease prevention. Then, natural compounds can be suitable inhibitors and since SENP2 is a protein involved in heart disease, so our aim was inhibition of SENP2 by natural products for heart disease treatment. Material and methods: Molecular docking and molecular dynamics simulation of natural products i.e. Gallic acid (GA), Caffeic acid (CA), Thymoquinone (TQ), Betanin, Betanidin, Fisetin, and Ebselen were done to evaluate the SENP2 inhibitory effect of these natural products. The toxicity of compounds was also predicted. Results: The results showed that Betanin constituted a stable complex with SENP2 active site as it revealed low RMSD, high binding energy, and hydrogen bonds. Further, as compared to Ebselen, Betanin demonstrated low toxicity, formed a stable complex with SENP2 via four to seven hydrogen bonds, and constituted more stable MD plots. Therefore, depending upon the outcomes presented herein, Betanin significantly inhibited SENP2 and hence may be considered as a suitable natural compound for the treatment of heart failure. Further clinical trials must be conducted to validate its use as a potential SENP2 inhibitor. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1663-9812 |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fphar.2022.817990/full; https://doaj.org/toc/1663-9812 |
| DOI: |
10.3389/fphar.2022.817990 |
| Access URL: |
https://doaj.org/article/8c922107345d4c7d8e5a2c9b2629a749 |
| Accession Number: |
edsdoj.8c922107345d4c7d8e5a2c9b2629a749 |
| Database: |
Directory of Open Access Journals |
